Why is Poly Medicure Ltd falling/rising?

Recent Price Movement and Market Context

Poly Medicure’s shares have been under sustained pressure, hitting a new 52-week low of ₹1,651.45 on the day. The stock has declined by 7.52% over the past week and 11.55% in the last month, significantly underperforming the Sensex, which fell by only 1.86% and 2.21% respectively over the same periods. Year-to-date, the stock is down 6.06%, compared to the Sensex’s modest 2.16% decline. This persistent weakness is further highlighted by the stock’s three consecutive days of losses, amounting to a 6.17% drop in that span.

Intraday trading saw the stock touch a low of ₹1,651.45, representing a 3.66% decline from the previous close. Moreover, Poly Medicure is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—indicating a bearish technical setup. The broader Medical Equipment/Supplies/Accessories sector also experienced a decline of 2.16%, suggesting sector-wide headwinds that have compounded the stock’s fall.

Investor participation appears to be waning, with delivery volumes on 13 Jan falling by 31.6% compared to the five-day average, signalling reduced buying interest. Despite this, liquidity remains adequate for trades up to ₹0.32 crore based on recent average traded values.

Fundamental Factors Weighing on the Stock

Despite its strong market position as the second largest company in its sector with a market capitalisation of ₹17,403 crore and annual sales of ₹1,712.13 crore, Poly Medicure’s recent financial performance has disappointed investors. The company reported flat results in September 2025, with a notably low dividend payout ratio of 10.70%, which may be viewed as a lack of shareholder returns. Additionally, the debtors turnover ratio stood at a low 4.02 times for the half-year, indicating slower collection efficiency that could impact cash flows.

Valuation concerns are also prominent. The company’s return on equity (ROE) is 12.4%, but it trades at a high price-to-book value of 5.8, suggesting that the stock is expensive relative to its book value. While the stock’s valuation is broadly in line with historical peer averages, the price-earnings-to-growth (PEG) ratio of 2.1 points to a premium valuation given the growth prospects. This expensive valuation may be deterring new investors, especially in light of the stock’s poor recent returns.

Disappointing Returns Despite Profit Growth

Over the past year, Poly Medicure’s stock has delivered a negative return of 34.70%, starkly contrasting with the Sensex’s 9.00% gain and the BSE500’s 8.97% positive return. This underperformance is notable given that the company’s profits have actually increased by 22.8% during the same period. The disconnect between profit growth and share price performance suggests that investors are concerned about other factors such as valuation, market sentiment, or operational challenges.

Institutional investors hold a significant 23.31% stake in the company, reflecting confidence from sophisticated market participants who typically have a deeper understanding of the company’s fundamentals. However, even this support has not been sufficient to arrest the recent decline in share price.

Long-Term Performance and Outlook

While the stock’s short-term performance has been disappointing, it has delivered strong returns over longer periods, with gains of 86.77% over three years and 210.83% over five years, outperforming the Sensex by a wide margin. This suggests that the company has underlying strengths and growth potential, but current market conditions and valuation concerns are weighing heavily on the stock price.

In summary, Poly Medicure’s recent share price decline is driven by a combination of weak short-term financial results, expensive valuation metrics, underperformance relative to the broader market, and reduced investor participation. Although the company maintains a solid market position and has demonstrated profit growth, these positives have not translated into share price gains in the near term, leading to the current downtrend.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →